Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | ME2 | P23368 | 1/20 | 0.59 |
| ▸ | ME1 | P48163 | 1/20 | 0.59 |
| ▸ | ME3 | Q16798 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245954 | 0.81 | MAPT (0.70) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL9125887 | 0.81 | GRM5 (0.72) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL30528252 | 0.81 | MAPT (0.86) | MAPTNPSR1LMNAALDH1A1ME2 | |
| SCHEMBL1902638 | 0.80 | GRM5 (1.00) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL28135156 | 0.80 | MAPT (0.78) | MAPTNPSR1LMNAALDH1A1ME2 | |
| SCHEMBL7840682 | 0.80 | MAPT (0.72) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL5245371 | 0.78 | MAPT (0.70) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL17834330 | 0.78 | MAPT (0.70) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL3299369 | 0.78 | MAPT (0.70) | GRM5MAPTNPSR1LMNAALDH1A1 | |
| SCHEMBL12781874 | 0.78 | MAPT (0.70) | GRM5MAPTNPSR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | claimed |
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | disclosed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| US-6906046-B2 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1135123-B1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D, INC. | 2003-04-10 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CXCL8, CASP8, IL18 | GRM5 3276/4885MAPT 2701/4885NPSR1 1302/4885 |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | GRM5 1121/4885MAPT 1939/4885NPSR1 1265/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | GRM5 819/4885MAPT 1634/4885NPSR1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.